Search Results
DS-7300 for the treatment of advanced solid tumors
Results from Phase I/II study of DS-7300a in advanced solid tumors
DS-7300: the B7-H3 targeting anti-body drug conjugate
B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab in advanced solid tumors expressing B7-H6
Dr Erika Hamilton presents study on DS6000 at ASCO22 for OncoAlert
B7-H3-CAR T cells for the treatment of pediatric adrenocortical carcinoma
B7-H3 Antibody-Drug Conjugates | Oncology Today with Dr Neil Love: The Emerging Role of...
New Treatment for Heavily Pretreated Small Cell Lung Cancer (SCLC)
Katie Nottberg 2019 Affibody indocyanine green for imaging of B7 H3 expression in breast cancer I5NG
Highlights from ESMO: DESTINY-Breast03
DESTINY-Gastric02: T-Dxd as a second-line treatment for HER2-positive gastric cancer
Virus Kills Cancer
